地诺单抗主要治疗什么病症呢？

Binds to RANKL, a transmembrane protein or soluble protein that is extremely important for the formation, function and survival of osteoclasts, which are responsible for bone resorption and regulate calcium release in the bone.

RANKL enhances osteoclast activity, a skeletal pathology process underlying bone metastasis from solid tumors. Similarly, giant cell tumors of bone contain bone mesenchymal stem cells that express RANKL and osteoclast-like giant cells that express RANK receptors, signaling through RANK receptors to cause osteolysis and tumor growth.

So, what diseases does denosumab mainly treat?

Indications for denosumab:

1. Prevent skeletal-related events in patients with multiple myeloma and patients with bone metastasis from solid tumors.

2. Treat adult patients with giant cell tumors of bone who are not suitable for surgery and have mature skeletal systems.

3. Treatment of hypercalcemia of malignant tumors that are resistant to bisphosphonates.

4. It is not used to treat patients with multiple myeloma and prevent their bone-related symptoms.

In addition, it should be noted that denosumab is a subcutaneous injection, which is simple to operate and affordable. During use, you need to pay attention to supplementing vitamin D and calcium.

In terms of adverse reactions, common adverse reactions of denosumab include: fatigue/weakness, low phosphate levels in the blood, and nausea.

In patients with giant cell tumor of bone, the adverse reactions of denosumab include joint pain, headache, nausea, pain, fatigue, and pain in the extremities.

Clinical results show that compared with zoledronic acid, denosumab effectively delays the incidence of first bone metastasis: lung cancer and other solid tumors: denosumab compared with zoledronic acid 20.5 months vs. 16.3 months; prostate cancer: denosumab compared with zoledronic acid 20.7 months vs. 17.1 months;

The key points for use are as follows: Injection dose: 120mg/time; Injection cycle: 4 weeks/time; Injection method: subcutaneous injection; Injection duration - at least 6 months; Auxiliary matters: If necessary, please supplement calcium and vitamin D to prevent hypocalcemia.